Navigation Links
Asthma & Allergy Foundation CEO Appointed to NIH Council

BETHESDA, Md., Jan. 10 /PRNewswire-USNewswire/ -- The Asthma and Allergy Foundation of America (AAFA) announces that its President and CEO, William M. McLin, has been appointed to the Council of the National Institute of Allergy and Infectious Disease (NIAID), an institute of the National Institutes of Health (NIH), for a four-year term. The Council is a chartered advisory committee that provides a diverse perspective on science, health and the human impact of diseases.

The Council serves as NIAID's main advisory body on key functions, including: performing peer review, advising on policy, reviewing programs, and developing and clearing concepts for program announcements, requests for applications and requests for proposals. NIAID often seeks the Council's advice before changing policies for training, health information dissemination, administration, budget and other areas.

McLin has been head of AAFA since 2001 at a time when asthma and allergic diseases in the U.S. have experienced alarming growth; prevalence has nearly doubled over the past 25 years. McLin helped the 55-year-old not-for-profit patient group transition into the 21st Century to better educate patients and caregivers, as well as advocate and conduct research for the asthma and allergy community.

McLin will serve on the advisory subcommittee of the Division of Allergy, Immunology, and Transplantation through October 31, 2012. During program reviews, the subcommittee advises on a program's effectiveness in meeting Institute goals and the needs of the allergy and immunology community.

Before coming to AAFA, McLin served as Director of Government Relations and Executive Vice President during his 20-year tenure with the Epilepsy Foundation of America. He also provided interim executive oversight services to numerous nonprofit organizations. Mr. McLin has held key positions with the National Health Council, the American Society of Association Executives, the President's Committee for Employment of People with Disabilities and the Public Advisory Roundtable of the American Thoracic Society.

NIAID conducts and supports basic and applied research to better understand, treat and prevent infectious, immunologic and allergic diseases. For more than 50 years, NIAID research has led to new therapies, vaccines, diagnostic tests and other technologies that have improved the health of millions of people around the world. Visit

AAFA is the leading national not-for-profit patient advocacy organization for people with asthma and allergies. It is dedicated to improving the quality of life for people with asthma and allergies through education, advocacy and research. For more information, visit

SOURCE The Asthma and Allergy Foundation of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nitric Oxide Monitoring of Little Benefit for Kids Asthma
2. NO help: Nitric oxide monitoring does not help most children with asthma
3. American Asthma Foundation Announces Breakthrough Discovery
4. Antifungal Drug May Help Ease Asthma
5. Fungal pill could provide asthma relief for 150,000 UK sufferers
6. Anti-fungal drug offers great benefits to some with severe asthma
7. Mayo Clinic study finds increased risk of pneumococcal disease in asthma patients
8. School Program Helps Cut Asthma Risks
9. Antacid Medication in Pregnancy May Increase Childhood Asthma
10. Next Safety Develops an Air-Based Asthma Medication Inhaler That Does Not Use a Refrigerant Propellant
11. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: